Safety of using genetic engineering biological agents in rheumatoid arthritis
The paper reviews the current trials of the safety of using genetic engineering biological agents (GEBA) in patients with rheumatoid arthritis. It is stated that before its start, GEBA therapy calls for thorough screening of patients to rule out communicable diseases (including tuberculosis) or a hi...
Main Authors: | N V Chichasova, E L Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2010-03-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/272 |
Similar Items
-
Combination therapy with leflunomide and genetic engineering biological agents
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-06-01) -
USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01) -
Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01) -
Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention
by: Natalia Vladimirovna Chichasova
Published: (2012-06-01) -
Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)